PDA EU00167 Practical Application of Risk-Based GMP & Quality Principles to Clinical Development of ATMPs

Ask a Question Exhibitor Standard Contract Clause

There has been a surge in clinical development of Advanced Therapy Medicinal Products (ATMPs), both in the EU and US. Many start-up companies, and now even large biopharmaceutical companies, are planning or have already entered into manufacturing these genetically engineered viruses and/or human cell products for clinical studies.

While the ground rules for Good Manufacturing Practices (GMPs) and quality of recombinant protein and monoclonal antibody manufacturing and control are well established, for ATMPs these are still under development. ATMP manufacturing and control presents unique GMP and quality challenges, such as the heightened concern about the safety/variability of the starting materials, the quality of the raw materials added during processing, the need to protect against adventitious agent contamination throughout the entire manufacturing cycle, the limited analytical methods available to characterize these ATMPs, and the reality that the administered clinical medicinal product is a complex living organism. In addition, the expedited pace of clinical studies for these ATMPs places enormous pressure on the need to also rapidly develop and enhance the manufacturing process control systems.

Patients in these clinical development programs need to be protected by common sense GMPs and quality principles. The available EMA/FDA regulatory authority guidance documents for ATMPs will be thoroughly examined. In addition, the core, risk-based principles presented in PDA’s 2018 Technical Report No. 81: Cell-Based Therapy Control Strategy, will be discussed.

  1. Identify the GMP and quality similarities and differences between protein medicinal products and ATMPs
  2. Explain how to apply a risk-based approach to the manufacturing and quality control of ATMPs
  3. Explain and justify the importance and underlying GMP and quality principles for ATMPs during clinical stages of development

Standard Registration

Member Price

€ 600

GovernmentMember Only

€ 600

Health AuthorityMember Only

€ 600

Early Career ProfessionalMember Only

€ 600

StudentMember Only

€ 600

AcademicMember Only

€ 600


€ 600

See Qualifying Criteria for Member Types.


WAYS TO REGISTER: 1. Online Registration   2. [email protected]

PDA MEMBERS: Please remember to log in before registering If you come from a Governmental or Health Authority Institution or from an Academic Organization, please contact [email protected] before registering.

If you need to apply for a visa to enter the event country, PDA Europe must be informed of this fact at least 4 weeks before the start of the event.

Day 1

Welcome and Introductions (30 min)

Overview of the ATMP Landscape (90 min)

  • Defining the critical terminology: CGTP, ATMP, CAT, OTAT, RMAT, etc.
  • How the diversity of ATMPs challenge the application of GMP and quality

Break (15 min)

ATMP GMP and Quality Risk Consequences (90 min)

  • Major differences between gene/cell-based medicines and protein-based medicines
  • Necessity of a risk-based approach

Day 2

Regulatory Authority Expectations During Clinical Development (90 min)

  • FDA guidances and risk-based considerations for ATMPs
  • EMA guidelines and comparison to FDA

Break (15 min)

Industry Practice in Applying Risk-Based Considerations to ATMPs (90 min)

  • PDA Technical Report No. 81
  • Lessons learned from industry practice
Agenda is subject to change.

PLEASE READ  PDA is not affiliated or contracted with any outside hotel contracting company. If someone other than PDA or the PDA chosen hotel contacts you suggesting that they represent any PDA event, they do not. It is PDA's recommendation that you book your hotel directly through the official PDA chosen hotel that is listed on our web site.